By inhibiting ECM1 and activating the GM-CSF/STAT5/Arg1 pathway to promote alternative macrophage M2, Shionone reduces the inflammatory response to accelerate tissue repair and is able to attenuate AKI in vitro and in vivo. Here, CSF2 is linked to acute kidney injury.